Literature DB >> 9315521

Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure.

A Matsumori1, K Ono, R Nishio, Y Nose, S Sasayama.   

Abstract

BACKGROUND: Recent studies suggest that cytokines such as tumor necrosis factor (TNF)-alpha and interleukins (ILs) are capable of modulating cardiovascular function and that drugs used in the treatment of heart failure have various modulatory effects on the production of cytokines. This study was performed to examine the effects of amiodarone (a drug shown to be beneficial in some patients suffering from heart failure) versus other antiarrhythmic agents on the production of cytokines in vitro. METHODS AND
RESULTS: Human peripheral blood mononuclear cells (PBMC) were obtained from healthy volunteers. PBMC were cultured with 0.1, 1, and 10 micromol/L of amiodarone, quinidine, disopyramide, and lidocaine in the presence of lipopolysaccharide. After 24 hours' incubation, TNF-alpha, IL-1beta, and IL-6 were measured in the culture supernatants by an enzyme-linked immunosorbent assay. TNF-alpha production was inhibited by amiodarone but stimulated by quinidine in a concentration-dependent manner. Disopyramide and lidocaine tended to increase TNF-alpha production. IL-6 production was decreased by amiodarone in all concentrations but was increased significantly by disopyramide. Modulation of IL-1beta production by amiodarone was biphasic and significantly increased at a concentration of 10 micromol/L.
CONCLUSIONS: These previously unrecognized immunomodulatory effects of amiodarone may contribute to its beneficial effects in heart failure patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315521     DOI: 10.1161/01.cir.96.5.1386

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

1.  Administration of amiodarone during resuscitation is associated with higher tumor necrosis factor-α levels in the early postarrest period in the swine model of ischemic ventricular fibrillation.

Authors:  Scott T Youngquist; James T Niemann; Atman P Shah; Joseph L Thomas; John P Rosborough
Journal:  J Interferon Cytokine Res       Date:  2013-05-09       Impact factor: 2.607

2.  Pleiotropic actions of amiodarone: still puzzling after half a century.

Authors:  Jordi Heijman; Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-09       Impact factor: 3.000

Review 3.  The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure.

Authors:  A Matsumori; S Sasayama
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

Review 4.  An approach to the treatment of pediatric myocarditis.

Authors:  Daniel Levi; Juan Alejos
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Cardiac function and the proinflammatory cytokine response after recovery from cardiac arrest in swine.

Authors:  James T Niemann; John P Rosborough; Scott Youngquist; Atman P Shah; Roger J Lewis; Quynh T Phan; Scott G Filler
Journal:  J Interferon Cytokine Res       Date:  2009-11       Impact factor: 2.607

6.  Modulation of both activator protein-1 and nuclear factor-kappa B signal transduction of human T cells by amiodarone.

Authors:  Shu-Meng Cheng; Wei-Hsiang Lin; Chin-Sheng Lin; Ling-Jun Ho; Tsung-Neng Tsai; Chun-Hsien Wu; Jenn-Haung Lai; Shih-Ping Yang
Journal:  Exp Biol Med (Maywood)       Date:  2014-07-29

Review 7.  Insights into pathogenesis and treatment of cytokines in cardiomyopathy.

Authors:  L Vadlamani; W T Abraham
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 3.955

8.  Appropriate candidates for statin use in heart failure.

Authors:  Hong Seog Seo
Journal:  Korean J Intern Med       Date:  2014-10-31       Impact factor: 2.884

9.  Neuroprotective effects of amiodarone in a mouse model of ischemic stroke.

Authors:  Masakazu Kotoda; Tadahiko Ishiyama; Kazuha Mitsui; Sohei Hishiyama; Takashi Matsukawa
Journal:  BMC Anesthesiol       Date:  2017-12-08       Impact factor: 2.217

10.  Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

Authors:  Fabian Sanchis-Gomar; Carl J Lavie; Daniel P Morin; Carme Perez-Quilis; Jari A Laukkanen; Marco V Perez
Journal:  Am J Cardiovasc Drugs       Date:  2020-10       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.